scholarly journals Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

2014 ◽  
Vol 233 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas C. Kreutzer ◽  
Armin Wolf ◽  
Martin Dirisamer ◽  
Rupert W. Strauss ◽  
Paul Foerster ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Group I ◽  
Group Ii ◽  
Central Retinal Vein

Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.

Intravitreales Ranibizumab versus isovolämische Hämodilution zur Behandlung des Makulaödems infolge von zentralem retinalem Venenverschluss: Zwölf-Monats-Ergebnisse einer prospektiven, randomisierten, multizentrischen Studie

2015 ◽  
Vol 1 (2) ◽  
pp. 82-83
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Multicenter Trial ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Central Retinal Vein

Zielsetzung: Dies ist eine prospektive, randomisierte, multizentrische, prüferinitiierte Studie zur Beurteilung der 12-Monats-Wirksamkeit der isovolämischen Hämodilution (IH) in Kombination mit sofortigen versus späteren intravitrealen Injektionen (IVI) von Ranibizumab 0,5 mg bei der Behandlung des Makulaödems auf dem Boden eines frühen zentralen retinalen Venenverschlusses (ZVV). Methoden: Augen mit nicht mehr als 8 Wochen zuvor aufgetretenem Makulaödem infolge eines ZVV erhielten entweder monatliche Ranibizumab-IVI in Kombination mit IH (Gruppe I; n = 28) oder IH allein (Gruppe II; n = 30). Von Monat 2 bis 12 konnten die Patienten in beiden Gruppen monatlich mit intravitrealem Ranibizumab behandelt werden. Die wichtigsten Zielgrößen waren die Zunahme der Sehschärfe und die Veränderung der zentralen Netzhaut-Dicke laut optischer Kohärenztomografie. Ergebnisse: Nach 12 Monaten zeigten die Augen in Gruppe I eine durchschnittliche Verbesserung um +28,1 (±19,3) Buchstaben, verglichen mit +25,2 (±20,9) Buchstaben in Gruppe II (p = 0,326). Diese Ergebnisse wurden mit einer signifikant geringeren Anzahl Injektionen in Gruppe II erreicht. Zudem benötigten 30% der Augen in Gruppe II über die 12-monatige Studiendauer hinweg gar keine Ranibizumab-IVI. Schlussfolgerung: Die Ranibizumab-IVI zusätzlich zur IH erwiesen sich als hochgradig wirksam in Bezug auf die Verbesserung der Sehschärfe und Reduktion des Makulaödems infolge von ZVV. Eine initiale IH bei frühem ZVV könnte eine erste Therapieoption bei Patienten sein, die gegenüber IVI Vorbehalte haben. Übersetzung aus Kreutzer TC, et al: Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 2015;233:8-17 (DOI: 10.1159/000369566)

scholarly journals Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Keiji Inagaki ◽  
Kishiko Ohkoshi ◽  
Sachiko Ohde ◽  
Gautam A. Deshpande ◽  
Nobuyuki Ebihara ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Disease Onset ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Group I ◽  
Group Ii ◽  
Best Corrected Visual Acuity

To assess the efficacy of subthreshold micropulse diode laser photocoagulation (SMDLP) for persistent macular edema secondary to branch retinal vein occlusion (BRVO), including best-corrected visual acuity (BCVA) > 20/40, thirty-two patients (32 eyes) with macular edema secondary to BRVO were treated by SMDLP. After disease onset, all patients had been followed for at least 6 months prior to treatment. Baseline Snellen visual acuity was used to categorize the eyes as BCVA ≤ 20/40 (Group I) or BCVA > 20/40 (Group II). Main outcome measures were reduction in central macular thickness (CMT) in optical coherence tomography (OCT) and BCVA at 6 months. In the total subject-pool at 6 months, BCVA had not changed significantly but CMT was significantly reduced. Group I exhibited no significant change in CMT at 3 months but exhibited significant reductions at 6 and 12 months. Group II exhibited a marginally significant reduction in CMT at 3 months and a significant reduction at 6 months. In patients with persistent macular edema secondary to BRVO, SMDLP appears to control macular edema with minimal retinal damage. Our findings suggest that SMDLP is an effective treatment method for macular edema in BRVO patients with BCVA > 20/40.

scholarly journals Intravitreal Steroid Injections in Macular Edema due to Central Retinal Vein Occlusion

2019 ◽  
pp. 38-44
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Side Effect ◽  
Lamina Cribrosa ◽  
Initial Application ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone ◽  
Central Retinal Vein

Retinal vein occlusion is the most common retinal vascular disease after diabetic retinopathy. An occlusion that affects the entire retinal venous system at the level of the lamina cribrosa is called central retinal vein occlusion (CRVO). One of the major complications that threaten visual acuity in CRVO patients is macular edema. Intravitreal dexamethasone implant is widely used in the treatment of macular edema. Efficacy has been shown in terms of short-term edema resolution and increased visual acuity. It seems that the effect on the macula decreases on average in the third month. It is a good option for patients who need to reduce the number of visits. There is no additional side effect except an increase in the incidence of cataracts with recurrent injections. Increasing of intraocular pressure appears to be a tolerable side effect. Their activities are reduced when they are done every six months or when the initial application period is long. Intravitreal steroid treatment is an effective alternative for macular edema secondary to CRVO.

scholarly journals Central retinal vein occlusion: A patient with systemic sclerosis

2016 ◽  
Vol 73 (9) ◽  
pp. 868-872
Author(s):  
Jelena Karadzic ◽  
Aleksandra Radosavljevic ◽  
Igor Kovacevic
Keyword(s):  
Visual Acuity ◽  
Systemic Sclerosis ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Case Reports ◽  
Immunosuppressive Treatment ◽  
Central Vein ◽  
Vein Occlusion ◽  
Central Retinal Vein

Introduction. Scleroderma (systemic sclerosis) is a severe chronic connective tissue disease, which results in involvement of numerous internal organs. Changes in the eye are the consequences of organ-specific manifestations of scleroderma or adverse effects of immunosuppressive treatment applied. Case report. We reported a 42-year-old woman with systemic sclerosis and acute deterioration of vision in the left eye, with visual acuity 0.9. After thorough clinical examination, including fluorescein angiography and optical coherence tomography, the diagnosis of nonischemic central retinal vein occlusion was made. Further biochemical, rheumatological and immunological investigation, apart from inactive systemic sclerosis, showed normal findings. Therefore, the cause of central retinal vein occlusion could only be attributed to the microvascular changes in systemic sclerosis. After three months, visual acuity deteriorated to 0.6 due to the development of cystoid macular edema. The patient received intravitreal injection of bevacizumab and after a single dose visual acuity improved to 0.9. After a 6- month follow-up, macular edema resolved and visual acuity stabilized. Conclusion. According to our knowledge and current data from the literature, central retinal vein occlusion is a rare vision threatening manifestation of scleroderma. There are only few published case reports on central vein occlusion in scleroderma patients. Examination of the ocular fundus is recommended for evaluation of vascular disease in patients with systemic sclerosis.

scholarly journals A Rare Cause of Unilateral Central Retinal Vein Occlusion in a Young Patient: Type III Mixed Cryoglobulinemia

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Sibel Doguizi ◽  
Mehmet Ali Sekeroglu ◽  
Mustafa Alpaslan Anayol ◽  
Pelin Yilmazbas
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Clinical Laboratory ◽  
Oral Prednisone ◽  
Mixed Cryoglobulinemia ◽  
Type Iii ◽  
Vein Occlusion ◽  
Central Retinal Vein

Purpose. To report a young male with unilateral central retinal vein occlusion (CRVO) associated with cryoglobulinemia.Case Presentation. A 33-year-old male without any known systemic or ocular disorder was admitted to our clinic with a complaint of visual loss for three days in his left eye. Based on the clinical, laboratory, and ophthalmological assessments, we diagnosed this case as type III mixed cryoglobulinemia with unilateral CRVO with macular edema. For treatment, two intravitreal ranibizumab injections were administered monthly and oral prednisone (64 mg/day) was begun. Subsequently, cryoglobulins became undetectable, macular edema decreased, and the visual acuity improved to 20/32 over an 8-week period. At 24 weeks, the patient’s visual acuity remained 20/32 and no recurrence was observed while the patient was still on prednisone (16 mg/day).Conclusion. Cryoglobulinemia should be considered in the differential diagnosis of the patients with CRVO.

Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion

2009 ◽  
Vol 147 (2) ◽  
pp. 298-306 ◽  
Author(s):  
Richard F. Spaide ◽  
Louis K. Chang ◽  
James M. Klancnik ◽  
Lawrence A. Yannuzzi ◽  
John Sorenson ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Prospective Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Central Retinal Vein
Sign in / Sign up

Export Citation Format

Share Document